Strides Pharma Science Limited has informed the Exchange regarding a press release dated October 17, 2025, titled "Strides and Incepta Partner to Expand Women s Health Access with WHO-Prequalified Contraceptive".
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma Science has announced a partnership with Incepta to expand access to a WHO-Prequalified contraceptive product focused on women's health. WHO prequalification is a globally recognised quality endorsement that allows the product to be procured by international agencies like UNICEF, UNFPA, and the WHO for public health programmes. The collaboration aims to broaden the reach of affordable, quality-assured contraceptives, particularly in emerging and developing markets. While specific financial terms or revenue projections have not been disclosed in this filing, the tie-up combines Strides' manufacturing and regulatory expertise with Incepta's distribution reach in key markets.
This partnership strengthens Strides' position in the global women's health and reproductive care segment, opening access to large institutional buyers and recurring volumes. It is a positive development for long-term growth, though near-term impact on earnings will depend on order volumes and contract awards from global health agencies.